Latest news with #BayerAktiengesellschaft
Yahoo
28-05-2025
- Business
- Yahoo
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Bayer Aktiengesellschaft (BAYRY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Bayer Aktiengesellschaft is a member of our Medical group, which includes 997 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for BAYRY's full-year earnings has moved 9.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Based on the latest available data, BAYRY has gained about 45.3% so far this year. Meanwhile, stocks in the Medical group have lost about 5.8% on average. This means that Bayer Aktiengesellschaft is performing better than its sector in terms of year-to-date returns. One other Medical stock that has outperformed the sector so far this year is BioCryst Pharmaceuticals (BCRX). The stock is up 43.5% year-to-date. For BioCryst Pharmaceuticals, the consensus EPS estimate for the current year has increased 359.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, a group that includes 11 individual stocks and currently sits at #41 in the Zacks Industry Rank. Stocks in this group have lost about 4.3% so far this year, so BAYRY is performing better this group in terms of year-to-date returns. On the other hand, BioCryst Pharmaceuticals belongs to the Medical - Drugs industry. This 161-stock industry is currently ranked #56. The industry has moved -0.9% year to date. Investors interested in the Medical sector may want to keep a close eye on Bayer Aktiengesellschaft and BioCryst Pharmaceuticals as they attempt to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report BioCryst Pharmaceuticals, Inc. (BCRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
13-05-2025
- Business
- Yahoo
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Bayer Aktiengesellschaft is a member of our Medical group, which includes 1001 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for BAYRY's full-year earnings has moved 7.6% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Our latest available data shows that BAYRY has returned about 39.3% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.7% on a year-to-date basis. This means that Bayer Aktiengesellschaft is performing better than its sector in terms of year-to-date returns. Another stock in the Medical sector, Boston Scientific (BSX), has outperformed the sector so far this year. The stock's year-to-date return is 15.2%. For Boston Scientific, the consensus EPS estimate for the current year has increased 2.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, which includes 11 individual stocks and currently sits at #42 in the Zacks Industry Rank. On average, this group has lost an average of 5.9% so far this year, meaning that BAYRY is performing better in terms of year-to-date returns. In contrast, Boston Scientific falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #167. Since the beginning of the year, the industry has moved +5.4%. Investors with an interest in Medical stocks should continue to track Bayer Aktiengesellschaft and Boston Scientific. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-03-2025
- Business
- Yahoo
Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Bayer Aktiengesellschaft is one of 1011 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for BAYRY's full-year earnings has moved 5.3% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Based on the latest available data, BAYRY has gained about 33.4% so far this year. In comparison, Medical companies have returned an average of 4.4%. This means that Bayer Aktiengesellschaft is outperforming the sector as a whole this year. Enhabit (EHAB) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 15.9%. In Enhabit's case, the consensus EPS estimate for the current year increased 32.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, which includes 12 individual stocks and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have gained about 6.3% so far this year, so BAYRY is performing better this group in terms of year-to-date returns. On the other hand, Enhabit belongs to the Medical Services industry. This 59-stock industry is currently ranked #77. The industry has moved +5.2% year to date. Going forward, investors interested in Medical stocks should continue to pay close attention to Bayer Aktiengesellschaft and Enhabit as they could maintain their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Enhabit, Inc. (EHAB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
